Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Apixaban on Digoxin PK in Healthy Subjects
NCT02262520Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2006
- Primary completion
- Mar 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Apixaban and Digoxin plasma concentration. Started Jan 2006; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02262520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262520.